Modality
ERT
MOA
GLP-1ag
Target
PD-1
Pathway
Proteasome
Cervical Ca
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
~Jan 2020
→ ~Apr 2021
Phase 3
Jul 2021
→ Jun 2028
Phase 3Current
NCT08184668
254 pts·Cervical Ca
2021-07→2028-06·Recruiting
254 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-192mo awayFast Track· Cervical Ca
2028-06-202.2y awayPh3 Readout· Cervical Ca
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Recruit…
Catalysts
Fast Track
2026-05-19 · 2mo away
Cervical Ca
Ph3 Readout
2028-06-20 · 2.2y away
Cervical Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08184668 | Phase 3 | Cervical Ca | Recruiting | 254 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |